Verapamil Effect in Cystic Fibrosis-related Dysglycemia

The investigators are conducting a pilot open-label pre/post interventional trial in adolescents and adults with cystic fibrosis (CF) and abnormal glucose tolerance or early CF-related diabetes mellitus (CFRD) to assess the safety and efficacy of verapamil on beta cell function and dysglycemia.

NCT Number	NCT07688070
Lead Sponsor	Rhode Island Hospital
Conditions	Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
Enrollment	30 participants
Start Date	2026-08-01
Primary Completion	2028-07-01 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-09